18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its recent approvals and product launches, Canada has also been making strides in its own biosimilars experience.

First, biosimilars of infliximab appear to be eroding the brand-name Remicade’s hold on the market in the Canadian province of Quebec. According to a Reuters analysis of government data, biosimilar infliximab options, primarily Inflectra, gained 11.4% of market share in January of this year, up from just 0.7% in February of 2017. By August 2019, 13.4% of infliximab-treated patients in Quebec were receiving a biosimilar.

Notably, biosimilars’ market share gains came despite the fact that, in February of 2019, a Quebec court ordered the province to restore full coverage of the brand-name drug after Quebec had previously determined it would reimburse only the biosimilar, saying that Janssen had not been given appropriate notice when the province changed its coverage.

Read Center for Biosimilars article